The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study - Wikidata - wikimedia - TriplyDB

The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study

The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study

http://www.wikidata.org/entity/Q35200032

about

Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.Don't stress about CRF: assessing the translational failures of CRF1antagonists.Addictions Neuroclinical Assessment: A reverse translational approach.Targeting psychologic stress signaling pathways in Alzheimer's disease.Time to connect: bringing social context into addiction neuroscience Alcohol Use Disorder Increases the Risk of Irritable Bowel Disease: A Nationwide Retrospective Cohort Study Persistent adaptation by chronic alcohol is facilitated by neuroimmune activation linked to stress and CRF Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics Control of chronic excessive alcohol drinking by genetic manipulation of the Edinger-Westphal nucleus urocortin-1 neuropeptide system.Emerging pharmacotherapies for alcohol use disorder.Substance use modulates stress reactivity: Behavioral and physiological outcomes.Fear Memory.The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.Alcohol Dependence Disrupts Amygdalar L-Type Voltage-Gated Calcium Channel Mechanisms.Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders.Probing for Neuroadaptations to Unpredictable Stressors in Addiction: Translational Methods and Emerging Evidence.Dysregulation of Brain Stress Systems Mediates Compulsive Alcohol Drinking.Paradoxical augmented relapse in alcohol-dependent rats during deep-brain stimulation in the nucleus accumbens.Effect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving.Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates.The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.Lost in Translation: CRF1 Receptor Antagonists and Addiction Treatment Pharmacotherapy of alcoholism - an update on approved and off-label medications.HPA Axis Gene Expression and DNA Methylation Profiles in Rats Exposed to Early Life Stress, Adult Voluntary Ethanol Drinking and Single Housing.Individual differences in the neuropsychopathology of addiction.Animal models of addiction.Prevention and reversal of social stress-escalated cocaine self-administration in mice by intra-VTA CRFR1 antagonism.Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking.Medications for alcohol use disorders: An overview.Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial.Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?Peripheral and prefrontal stress system markers and risk of relapse in alcoholism.Evaluation of Alcohol Preference and Drinking in msP Rats Bearing a Crhr1 Promoter Polymorphism.Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework

P2860

Q30366964-F20AE9D3-DB3A-417C-8861-33C5F0CC0FD5 Q30399543-3702FC98-09F8-4AEC-85AC-64212622828C Q30399803-35722FA6-9328-4E80-841F-9AD597EF9C3B Q33820375-F642FE19-889D-461C-8915-70915129E6F0 Q33924603-77293FB8-1E95-4F82-9F7A-BB27F0F4BB90 Q36421071-42201BED-38E2-4A82-B5D3-6B241D7A5696 Q36865231-E24822A0-18BD-4CE5-B68D-D5A5ED31F356 Q37397620-67DDE693-B4A2-45F6-8F7D-C1652D985ACD Q37633242-25B1097C-E384-45A3-B757-1BE1F533AA77 Q38689594-7DA00144-C93C-4585-9B9E-C46174ECD363 Q38747433-9C1D6C53-1C2C-4C14-8F12-DFAC9C52810F Q38777375-7A51815E-DB65-45E4-86D6-3C5F371C952B Q38813579-C0997979-37D3-4147-BAB3-CED6125DE574 Q38863864-D47821A6-37DA-49A4-90AF-2678B2FCF038 Q38980046-A9DCF4D1-4CFC-4F3F-851C-B4A87E57C98D Q39302789-1A310D85-9AD5-4F4A-8710-0069F627D07A Q39365977-37C8B42E-B547-4B2C-9978-0A0E453F6466 Q39667131-7224F80F-19DD-4E3A-8CA4-2A6DE7E15678 Q40402603-AFF961BF-B6DB-425E-B221-1F99BDD9F768 Q42623009-19B1ECBE-4008-4478-9AB3-C0F156935B4B Q42701005-DCAFC157-54BA-4F48-91C2-C8971730EE97 Q42701011-C74CBFA6-BD5F-4153-9DF4-E70866E46B2F Q43061723-260138FB-08F1-451C-AD34-54E886349C2B Q43068421-7B596AC2-D4DD-4174-89FC-18CC742BC45F Q47150637-51549CA6-39D9-468F-8AF1-3972C4CC8588 Q47156600-E8BDD827-EA30-4EC0-89D6-23F30C673130 Q47786671-6651A5E8-ED29-4368-BFF1-52E802EEDE28 Q47836940-825A5A27-55E9-4B6A-8560-AAE9B6B3608B Q47942161-75F30832-DD9E-4325-89A2-25326F892C0F Q47975121-3AB601D6-32C1-4173-ADB7-C8E86B215E3E Q47987383-0341E84E-D1FB-4118-B8E8-E697642AA6BE Q48305886-A62B44A0-9C45-4C78-ABA2-38F03C238F3D Q50551082-30FC4E44-302A-4175-9E25-F86D03FD8BFF Q52315997-A91D21E3-49CB-47B7-B153-19EF7FA20311 Q58788199-A47F3295-6EF2-47E5-BDD4-E9A479DC6791

P2860

The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study

http://www.wikidata.org/entity/Q35200032

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The corticotropin releasing ho ...... ed experimental medicine study

@ast

The corticotropin releasing ho ...... ed experimental medicine study

@en

type

label

The corticotropin releasing ho ...... ed experimental medicine study

@ast

The corticotropin releasing ho ...... ed experimental medicine study

@en

prefLabel

The corticotropin releasing ho ...... ed experimental medicine study

@ast

The corticotropin releasing ho ...... ed experimental medicine study

@en

P1433

Q35200032-A2FA0594-B3CD-4FB1-96E3-57BD496A256B

P1476

Q35200032-F1E4BC6D-A7AB-4F4B-9CA4-9221F13C997B

P2093

Q35200032-09F3DF2F-E0E3-4C21-9DD9-EAB3B42214E9

Q35200032-1453AB1C-9552-4FF2-A50C-F62117B38722

Q35200032-2F2F1792-3333-4458-814E-91E14BD4A691

Q35200032-6039AC70-F4B3-4EDB-90BF-98846A05F442

Q35200032-9510DBFD-CA70-4D20-AA77-D8925593DE03

Q35200032-9C19F913-02D3-430E-806D-652AFACF476F

Q35200032-A6D91250-3079-4D1D-973A-EB15D5EBDDB2

Q35200032-AEF1BF35-FF86-444C-852B-668C8DF780A4

Q35200032-B8BF926E-E090-4676-8127-AE64A56F1543

Q35200032-C4EFE603-5692-4B4E-B042-FC4E9ECCA3B4

P2860

Q35200032-02A239D4-4C39-415E-BB33-4334E56D0F9E

Q35200032-04193E71-271B-48BE-86BC-EB2F435255B1

Q35200032-11230803-2428-4A52-8D92-6FCF09C9E08C

Q35200032-1127882A-7AB0-44D2-89B1-EA9F53E58103

Q35200032-136533CA-8CD3-4B19-BA2F-998E4D3C0726

Q35200032-19CDCBD1-DC63-42F3-9A0A-7AB36C549D4F

Q35200032-27F57D6A-1146-4348-B501-F9AF14030928

Q35200032-3230F7AA-2DF2-43F2-A02B-CF207EA23E51

Q35200032-3E814BAF-3784-4EC0-B6CD-407C2AD6BA1F

Q35200032-4009D34E-7DB1-4BED-B643-58E1CC8362EC

P2888

Q35200032-BD3DCDCE-D422-48D4-8EB8-A3791BD6B24A

P304

Q35200032-433D63B4-2C72-48D8-985C-4186564F69B2

P31

Q35200032-D2A9B830-EA8F-4319-BE3D-7A5C30FD5CA7

P356

Q35200032-16C786EC-F5B6-4F7D-A790-57C716C8D01E

P407

Q35200032-92BA031C-53D4-4DEB-995D-7D1285213DAD

P433

Q35200032-8E3901DB-E23E-45A8-A649-1D033F01CD4F

P478

Q35200032-C7C0CBB3-89EC-49E0-B9B6-1B3073E4F715

P50

Q35200032-E1932C3B-7389-46ED-8421-6D344AC9D760

Q35200032-E35ED77F-4CD4-49B9-8D41-34B844FE694F

P577

Q35200032-9008780B-A85E-404A-987D-79333B8C4FE2

P5875

Q35200032-0E712639-003A-4EFD-B948-8CA07B0DC015

P6179

Q35200032-F28A626A-2681-4EDB-B177-F4E76AD7056E

P698

Q35200032-D1DB90BB-BF39-45BC-8500-E8CA3DAC2345

P932

Q35200032-2C162080-FDF7-419F-85E4-D726793410AD

P356

P1433

Neuropsychopharmacology

P1476

The corticotropin releasing ho ...... ed experimental medicine study

@en

P2093

Annika Thorsell

http://www.w3.org/2001/XMLSchema#string

Daniel E Rio

http://www.w3.org/2001/XMLSchema#string

David T George

http://www.w3.org/2001/XMLSchema#string

Laura E Kwako

http://www.w3.org/2001/XMLSchema#string

Marta Concheiro

http://www.w3.org/2001/XMLSchema#string

Melanie L Schwandt

http://www.w3.org/2001/XMLSchema#string

Primavera A Spagnolo

http://www.w3.org/2001/XMLSchema#string

Rajita Sinha

http://www.w3.org/2001/XMLSchema#string

Reza Momenan

http://www.w3.org/2001/XMLSchema#string

Sebastien Anizan

http://www.w3.org/2001/XMLSchema#string

P2860

Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?

Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

AFNI: software for analysis and visualization of functional magnetic resonance neuroimages

Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats

The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting.

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.

Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes

The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.

P2888

P304

1053-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2014.306

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Marilyn Huestis

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268788183

http://www.w3.org/2001/XMLSchema#string

P6179

1031908992

http://www.w3.org/2001/XMLSchema#string

P698

25409596

http://www.w3.org/2001/XMLSchema#string

P932

4367465

http://www.w3.org/2001/XMLSchema#string